Volume - 14 | Issue - 07 | July - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

THERAPEUTIC EVOLUTION OF STATINS FROM NATURAL ORIGINS TO ITS BEST-IN-CLASS SYNTHETIC DERIVATIVES: A SYSTEMATIC EVALUATION

Pharmaceutical Science

Megha Desai* Research Scholar *Corresponding Author

Prof. Susy Albert Professor

ABSTRACT

Statins are basically lipid-lowering agents that mitigate disease progression and reduce mortality rates in individuals at elevated risk of cardiovascular disorders. These pharmacological agents represent the most frequently prescribed therapeutic option for reducing cholesterol which lessen blood counts of LDL cholesterol by minimizing cholesterol plaque accumulation in artery walls. Statins manages & treats hypercholesterolemia, also act as inhibitors of the hydroxymethylglutaryl-CoA reductase enzyme, by doing so reduces total cholesterol, LDL, and triglycerides while enhancing HDL levels in blood. The US FDA has licensed several statin formulations, including lovastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin, & simvastatin. Healthcare practitioners are prescribing these drugs adjuvant to dietary and lifestyle modifications to treat hypertriglyceridemia, hyperlipoproteinemia hypercholesterolemia. These pharmacological agents serve as cornerstone interventions in both primary and secondary prophylaxis against coronary artery This analysis will provide a meticulous evaluation of the pharmacokinetic properties and therapeutic efficacy of statins, alongside a comprehensive exploration of their clinical indications, mechanisms of action, and contraindications in lipid management.

KEYWORDS

hypercholesteremia, lipid disorder, statins.

INTRODUCTION

The inception of 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, referred as statins, in 1987 marked a remarkable advancement in pharmacologically managing cardiovascular diseases (CVDs) [1]. Extensive clinical research has validated the lipid-lowering efficacy of statins, alongside their cholesterol-independent, pleiotropic gene action, in turn enhancing endothelial functionality, attenuating vascular inflammation, and promoting plaque stabilization[2].

Statins have demonstrated potential as antihypertensive agents due to their reducing capability both systolic and resting blood pressure [3]. Although the precise mechanism underlying their antihypertensive action remains incompletely understood, scientific investigations suggest that statins may facilitate vasodilation through the activation of molecular pathways regulating vascular tone [4].

Additionally, statins contribute in equilibrating atherosclerotic plaque, which lessen thrombosis occurrence chance, a pathological process wherein a clot forms at the site of arterial plaque accumulation, potentially obstructing blood flow. These agents may also mitigate the risk of pulmonary embolism, characterized by the dislodgement of a thrombus or lipid plaque, leading to occlusion in the pulmonary vasculature, which can result in symptoms ranging from chest pain and dyspnea to sudden mortality [5].

Furthermore, emerging evidence suggests that statins exert a protective effect against venous thromboembolism, a condition wherein a circulating thrombus originating from the venous system becomes lodged in a distal vascular site [6].

While statins are readily embraced, detrimental effects like fatigue and myalgia may occur in some individuals [7]. A rare but clinically significant adverse reaction, statin-induced myopathy, characterized by progressive muscle degeneration, has been linked to genetic variants affecting hepatic uptake and metabolism of these agents [8].

During the 1950s and 1960s, accumulating evidence established raised plasma cholesterol has proven risky for cardiovascular disease, prompting the search for pharmacological interventions capable of reducing its concentration [9].

Following lovastatin capitalisation, six more statins were launched in the market, including the semi-natural derivatives simvastatin and pravastatin, and man-made statins: atorvastatin, fluvastatin, rosuvastatin & pitavastatin [10]. Among these, atorvastatin remains the most widely prescribed [11].

In 1976, Compactin (mevastatin) was discovered by a biochemist Akira Endo, working in Japanese firm name Sankyo Company. He isolated this bioactive compound from Penicillium citrinum which was a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase enzyme, which was the first statin administered to humans [12] and its mechanism of action is shown in Figure 1.



Figure 1: Schematic mechanism of action of statins: Image from Physiopedia

Experimental studies demonstrated Compactin's cholesterol-lowering effects in monkeys, rabbits, and dogs. However, its inefficacy in rats raised concerns until subsequent research attributed this phenomenon to compensatory upregulation of HMG-CoA reductase in hepatic tissue [13].

Clinical trials of Compactin commenced in Japan, accompanied by further investigations worldwide [14]. Further, in 1978, Alfred Alberts and comrades identified lovastatin (mevinolin/monacolin K), a very effective HMG-CoA reductase inhibitor, from fermentation broth of Aspergillus terreus. Independently, Endo also discovered the same compound within a year [15].

After preclinical safety assessments demonstrated no detrimental impact, which led to human trials of lovastatin in 1980. At the same time, concurrent studies involving Compactin were halted by Sankyo in same year, citing potential toxicity observed in animal models. Despite this setback, subsequent safety evaluations of lovastatin revealed no significant toxicity, prompting Merck to resume its clinical development program in 1983, initially targeting individuals at high risk of myocardial infarction [16].

The success of lovastatin spurred chemical modifications of naturally derived statins to enhance their pharmacological efficacy. Merck researchers synthesized simvastatin, a synthetic analogue of lovastatin, exhibiting multi-fold increase in inhibitory activity. Researchers at Warner-Lambert developed atorvastatin with chemical modification, demonstrating superior potency—approximately three to four times higher than lovastatin in preclinical rat models. Subsequently, additional statins, including cerivastatin, simvastatin, and cerivastatin, were synthesized by various pharmaceutical companies [17].

On this day September 1, 1987, lovastatin became the first statin to receive US FDA approval, revolutionizing hypercholesterolemia management with sales surpassing $1 billion USD in peak annually [18].

Following year, Simvastatin was approved in Sweden and distributed globally. Subsequently FDA approved pravastatin in 1991, fluvastatin in 1994, atorvastatin in 1997, cerivastatin in1998, and rosuvastatin in 2003 [19].

In 2012, the FDA revised statin labelling to reflect emerging safety concerns, including a modest elevation of glucose levels in blood which is linked to increasing risk of another disease- type 2 diabetes. Additionally, cognitive effects such as memory impairment and confusion were acknowledged as potential adverse reactions [20].

RESULTS & DISCUSSION

Statins serve as the primary pharmacological intervention for dyslipidemia, particularly in cases marked by uplifted low-density lipoprotein cholesterol (LDL-C) in blood. Lipid-modulating agents encompass several pharmacological classes, including cholesterol absorption inhibitors, fibric acid derivatives, hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins), fibric acid derivatives, nicotinic acid, and bile acid sequestrants [21]. They exhibit distinct mechanisms of action and varying efficacy in lipid modulation, necessitating drug selection based on the specific lipid abnormality [22].

Lipid-lowering therapy, particularly with statins, grants great benefits in preventing coronary artery disease in individuals with abnormality in lipid profile. However, the precise mechanisms underlying these therapeutic effects remain incompletely elucidated. Atherosclerotic regression is observed in small patient population, and displaying clinical benefits of lipid decline within six months—before significant plaque regression occurs—suggesting additional contributory mechanisms such as plaque stabilization, endothelial function restoration, and reduced thrombogenic potential [23].

The FDA has approved statins for several indications [24], including: Atherosclerosis, primary prevention of atherosclerotic cardiovascular disease (ASCVD), secondary prevention in patients with established ASCVD, hypertriglyceridemia, hyperlipidemia and mixed dyslipidemia, Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia), homozygous familial hypercholesterolemia in adults and paediatric familial hypercholesterolemia Statins are further classified based on their origin and solubility profile, distinguishing between lipophilic and hydrophilic compounds [25].

Classification Of Statins

- **Based On Source:**
- **Naturally Derived:** Pravastatin, Simvastatin, Lovastatin
- **Synthetically Produced:** Atorvastatin, Fluvastatin
- **Based on Solubility:**
- **Hydrophilic Statins**: Pravastatin, Rosuvastatin
- **Lipophilic Statins:** Fluvastatin, Atorvastatin, Simvastatin.

Pharmacological Properties & Clinical Uses for all the drugs are described below covering aspects in order- pharmacological classification & therapeutic role, pharmacokinetics & biochemical activation, discovery, development, & natural occurrence, clinically and historically followed by its chemical structure:

1) **Lovastatin (Mevacor):** Lovastatin, marketed as Mevacor, is indicated for hypercholesterolemia management and alleviating ASCVD risk. It is prescribed alongside lifestyle modifications and is administered orally [26].

Pharmacologically, it acts as a competitive inhibitor of HMG-CoA reductase which is the rate-limiting enzyme in biosynthesis of cholesterol, impeding the conversion of HMG-CoA to mevalonate, a key precursor in cholesterol production [27]. By reducing cholesterol synthesis in liver, LDL receptors get upregulated, following clearance of LDL from circulation [28].

Pharmacokinetically, it is prodrug and administered as an inactive gamma-lactone form, which undergoes in vivo hydrolysis to its active form β-hydroxy acid, the active pharmacological entity [29]. Metabolized predominantly by hepatic cytochrome P450 (CYP3A4) enzymes, its bioavailability and elimination are influenced by metabolic interactions [30].

The first explicit HMG-CoA reductase inhibitor, lovastatin got patented in 1979 and FDA approval in 1987 [31]. Naturally occurring in red yeast rice, oyster mushrooms (Pleurotus ostreatus), and Pu-erh tea, it is also biosynthesized by filamentous fungi, including Penicillium citrinum [32]. The discovery of compactin (mevastatin) in the 1970s paved the way for lovastatin's clinical development, following its characterization in Aspergillus terreus cultures [33].

Lovastatin revolutionized lipid management, becoming the first statin approved for therapeutic use, with subsequent advancements leading to the development of simvastatin, atorvastatin, and other structurally optimized derivatives [34]. Initially investigated alongside compactin, lovastatin's clinical progression continued after additional safety evaluations confirmed tolerability and efficacy in high-risk cardiovascular patients [35].



Figure 2: Chemical structure of Lovastatin [25]

2) **Atorvastatin (Lipitor):** Atorvastatin, is widely utilized for lipid management and the primary and secondary prevention of ASCVD [36] and effective in reducing LDL-C and mitigates cardiovascular risk in hypercholesterolemic, & in patients with metabolic syndrome, or familial dyslipidemia [37]. As a first-line lipid-modulating agent, it exhibits superior potency compared to earlier statins, making it a key therapeutic choice in modern cardiovascular pharmacology [38].

Pharmacologically, it acts as a competitive inhibitor of HMG-CoA reductase which is the rate-limiting enzyme in biosynthesis of cholesterol, impeding the conversion of HMG-CoA to mevalonate, a key precursor in cholesterol production [39]. The suppression of endogenous cholesterol biosynthesis triggers upregulation of LDL receptors on hepatocytes, leading to amplified clearance of circulating LDL-C and lowering of cholesterol levels [40]. Additionally, atorvastatin lowers triglyceride and modestly elevates HDL-C, contributing to comprehensive lipid regulation and cardiovascular protection [41].

Pharmacokinetically, atorvastatin is a fully synthetic compound and exhibits high oral bioavailability, [42] and attains peak plasma concentrations within 1–2 hours, with hepatic uptake being the primary mechanism of distribution [43]. It is extensively metabolized by cytochrome P450 (CYP3A4) enzymes, generating active hydroxylated metabolites that contribute to its prolonged pharmacological activity [44]. It is excreted via biliary pathways, with minimal renal clearance, making dose adjustments necessary in hepatic impairment but generally not in renal dysfunction [45], and also shows extended elimination half-life (~14 hours), allowing sustained LDL reduction and once-daily dosing convenience [43].

Atorvastatin was developed as part of efforts to enhance the lipid-lowering efficacy of existing statins [46]. Unlike lovastatin and simvastatin, which were derived from fungal metabolites, atorvastatin was rationally designed through synthetic modifications to optimize pharmacokinetics and potency [47]. Patented in 1986, atorvastatin underwent rigorous clinical evaluation before receiving FDA approval in 1996, proving superior LDL-C reduction compared to earlier statins [48]. Comparative Advantages: With enhanced lipophilicity and longer half-life, it demonstrated greater efficacy in LDL reduction, making it the preferred statin for aggressive lipid control strategies [25].

Atorvastatin's approval marked a transformative moment in cardiovascular pharmacotherapy, elevating statins to the forefront of cholesterol management and ASCVD prevention [49]. Due to its potency, tolerability, and broad clinical applications, atorvastatin became one of the most prescribed statins globally [38]. Meta-analyses have revealed its potential benefits in renal function preservation (eGFR stabilization) and proteinuria reduction, though its impact on kidney failure remains inconclusive [50]. Long-term studies have consistently shown significant reductions in cardiovascular disorders, making it effective therapy in patients with high risk [51].



Atorvastatin

Figure 3: Chemical structure of Atorvastatin [25]

3) **Fluvastatin (Lescol):** Fluvastatin is utilized for governing hypercholesterolemia and preventing ASCVD [52]. As a lipid-lowering agent, it reduces LDL-C and mitigates cardiovascular risk in patients with dyslipidemia, metabolic syndrome, and familial hypercholesterolemia [53]. Unlike other statins, fluvastatin exhibits minimum drug-drug interactions, enhancing its safety profile in patients requiring concomitant therapies [54].

Pharmacologically, also a competitive inhibitor of HMG-CoA reductase which is the rate-limiting enzyme in biosynthesis of cholesterol, impeding the conversion of HMG-CoA to mevalonate, a key precursor in cholesterol production [55], leading to increased expression of LDL receptors, facilitating greater LDL-C hepatic clearance from circulation and contributing to overall lipid modulation [25].

Pharmacokinetically, Fluvastatin is readily absorbed via oral administration, and peak plasma concentrations is achieved within an hour [56]. Unlike lovastatin, simvastatin, and atorvastatin, fluvastatin does not undergo extensive metabolism via CYP3A4 [57]. Instead, it is primarily metabolized by CYP2C9, making it less susceptible to interactions with CYP3A4 inhibitors [58]. However, co-administration with fluconazole, a potent CYP2C9 inhibitor, can elevate fluvastatin plasma levels [59]. It exhibits hepatic metabolism and is predominantly excreted via biliary pathways, with minimal renal clearance, necessitating caution in patients with hepatic impairment [57]. Elimination half-life varies between 2–3 hours, distinguishing it from other statins that exhibit longer durations of action [60].

Patented in 1982, fluvastatin was developed as part of efforts to create statins with improved pharmacokinetic profiles and reduced drug-drug interactions. FDA approval in 1994 marked its entry into clinical use as the first fully synthetic statin designed with a lower interaction potential compared to other agents in its class [61]. Unlike lovastatin and simvastatin, which are derived from fungal metabolites, fluvastatin was chemically synthesized to optimize its pharmacological and safety profile [25].



Fluvastatin

Figure 4: Chemical structure of Fluvastatin [25]

4) **Pravastatin (Lipostat)-** Pravastatin, also used for primary and secondary prevention of ASCVD and managing dyslipidemia [64]. It effectively lowers LDL-C while demurely elevating HDL-C, making it a fundamental component of cardiovascular risk reduction strategies [65]. Pravastatin is recommended after dietary and lifestyle modifications fail to sufficiently improve cholesterol levels, and its overall efficacy is considered somewhat lower than other statins [66].

Pharmacologically, Pravastatin functions through two lipid-lowering pathways: by inhibition of HMG-CoA Reductase enzyme as a reversible competitive inhibitor, it sterically blocks HMG-CoA reductase ultimately preventing endogenous cholesterol synthesis in liver; and by reducing in lipoprotein output by decreasing synthesis of VLDL, which is a precursor of LDL. This downregulation of VLDL synthesis increases hepatocellular LDL receptor expression, enhancing LDL uptake from circulation and thereby lowering plasma LDL-C levels [67].

Pharmacokinetically, pravastatin exhibits minimal hepatic metabolism, leading to lower systemic drug interactions. It is well-absorbed and reaches top plasma concentrations within 1–1.5 hours post oral administration. It undergoes limited cytochrome P450 metabolism, avoiding significant interactions with CYP3A4 inhibitors. Primarily cleared renally (~50%) and hepatically (~50%), reaches half-life of approx. 1.5–2 hours, requiring dosing once-daily [68]. Due to its hydrophilic nature, pravastatin exhibits lower tissue penetration, potentially minimizing adverse effects associated with statin therapy [69].

Pravastatin, initially referred to as CS-514, is a derivative of ML-236B (compactin), a fungal metabolite discovered from Penicillium citrinum by researchers at Sankyo Pharma Inc in 1970s [70]. Pravastatin was structurally optimized from compactin to enhance potency and hydrophilicity, reducing lipophilic-related toxicity [69], patented in 1980 and approved for medical use in 1989, becoming one of the first statin introduced for clinical lipid management [71].

Pravastatin demonstrated efficacy in lowering LDL-C levels, though its potency is considered modestly lower compared to atorvastatin or simvastatin [72]. Due to minimal CYP450 metabolism, pravastatin exhibits fewer drug-drug interactions, making it a preferred choice for patients with multiple concomitant medications [58]. While primarily used in hypercholesterolemia management, pravastatin has been evaluated for renal function preservation and anti-inflammatory effects in cardiovascular disease progression [73].



Pravastatin

Figure 5: Chemical structure of Fluvastatin [25]

5) **Rosuvastatin (Crestor)-** Rosuvastatin is a synthetic, hydrophilic statin indicated for managing dyslipidemia and preventing primary and secondary ASCVD [74]. It is among the most potent statins, exhibiting superior LDL-C reduction compared to earlier statins [75]. Its clinical utility extends to individuals with hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia, often prescribed alongside dietary modification, exercise, and weight management strategies to optimize cardiovascular protection [76].

Pharmacologically, rosuvastatin also acts as a competitive inhibitor of HMG-CoA reductase which is the rate-limiting enzyme in biosynthesis of cholesterol, impeding the conversion of HMG-CoA to mevalonate [74]. Resulting in upregulating of LDL receptors on hepatocytes, thereby elevating LDL clearance and reducing circulating LDL-C concentrations [77]. Additionally, rosuvastatin demonstrates modest triglyceride reduction and HDL-C elevation, contributing to comprehensive lipid modulation [78]. However, reductions in plasma coenzyme Q10 levels and alterations in collagen turnover markers have been reported, potentially affecting cardiac metabolism in patients with chronic heart failure [79].

Pharmacokinetically, Rosuvastatin exhibits moderate oral bioavailability (~20%) and plasma concentration reaching to its peak post-administration within 3–5 hours [80]. Unlike lipophilic statins (e.g., atorvastatin, simvastatin), rosuvastatin undergoes minimal hepatic metabolism via cytochrome P450 (CYP2C9), resulting in fewer drug-drug interactions [58]. Predominantly cleared via biliary excretion, with approximately 90% recovered unchanged in feces and limited renal clearance (~10%), necessitating dose adjustments in patients with significant renal impairment [80]. Exhibits an extended half-life (~19 hours), allowing for once-daily dosing and sustained lipid-lowering effects [81].

Patented in 1991, rosuvastatin was synthesized to enhance lipid-lowering efficacy while maintaining a hydrophilic profile, reducing penetration into non-hepatic tissues and potentially lowering myotoxicity risks [82]. FDA approval in 2003 marked its introduction into clinical use, rapidly establishing it as a high-potency statin suitable for aggressive LDL-C reduction strategies [83]. Unlike compactin-derived statins (e.g., lovastatin, pravastatin), rosuvastatin was entirely synthetically designed to optimize pharmacokinetic stability and receptor affinity [84].

While rosuvastatin demonstrates superior LDL-C reduction, concerns regarding adverse effects, particularly myopathy, renal impairment, and coenzyme Q10 depletion, have been highlighted [85]. Despite its greater efficacy, some critics argue that rosuvastatin may carry higher risks of adverse events compared to other statins [86]. Research has explored potential cardiovascular benefits beyond lipid lowering, but evidence suggests its effects on chronic heart failure may be offset by metabolic alterations [79].



Figure 6: Chemical structure of Rosuvastatin [25]

6) **Simvastatin (Zocor)-** Simvastatin is a lipophilic statin managing and preventing dyslipidemia and primary and secondary ASCVD [87]. It is prescribed to lower elevated lipid levels, particularly LDL-C, and given adjuvant to dietary modifications, exercise, and weight management to optimize cardiovascular risk reduction [88]. Simvastatin is widely utilized in patients with substantial risk of cardiovascular related events like metabolic syndrome, diabetes and coronary artery diseases [89].

Pharmacologically, also acting as a competitive inhibitor of HMG-CoA reductase which is the rate-limiting enzyme in biosynthesis of cholesterol [90]. This inhibition leading upregulation of LDL receptors, elevating LDL clearance and reducing circulating LDL-C concentration in blood [91]. Additionally, simvastatin modestly increases HDL-C and decreasing triglycerides, contributing to comprehensive lipid modulation and cardiovascular protection [92].

Pharmacokinetically, simvastatin is a prodrug and administered as an inactive form, which undergoes in vivo hydrolysis to its active form β-hydroxy acid and plasma concentrations reaches peak post-administration within 1–2 hours [87]. Primarily metabolized by cytochrome P450 (CYP3A4), making it vulnerable to drug-drug interactions with various CYP3A4 inhibitors like antifungals, grapefruit juice, and certain antibiotics [93]. Predominantly cleared via biliary excretion, with minimal renal clearance, necessitating caution in patients with hepatic impairment [94]. Exhibits a short half-life (~2 hours), requiring once-daily dosing, typically in the evening to align with peak endogenous cholesterol synthesis [95].

Simvastatin is derived from the fungus Aspergillus terreus, similar to its precursor lovastatin [96]. Patented by Merck in 1980, simvastatin underwent extensive clinical evaluation before receiving FDA approval in 1992, establishing itself as a potent lipid-lowering agent [97]. Developed as a semi-synthetic derivative of lovastatin, simvastatin was designed to enhance LDL-C reduction keeping safety profile encouraging [98].

Simvastatin exhibited sustainable decline in cardiovascular events, including coronary revascularization, stroke, & myocardial infarction [52]. While effective, drug interactions via CYP3A4 metabolism necessitate careful monitoring, distinguishing it from hydrophilic statins like pravastatin and rosuvastatin, which exhibit fewer metabolic interactions [30]. Beyond lipid-lowering, simvastatin has also been investigated for endothelial-stabilizing effects in cardiovascular disease management & anti-inflammatory effects [99].

Figure 7: Chemical structure of Simvastatin [25]

CONCLUSIONS

Over the past several decades, the field of pharmacotherapy has undergone a transformative evolution, characterized by the rapid development and clinical implementation of novel therapeutic agents. The unprecedented advancements in drug discovery, coupled with accelerated translation from preclinical research to human trials, have been predominantly governed by the consistent attainment of success of lipid-modulating therapies in clinical practice. Statins, in particular, have demonstrated profound efficacy in reducing LDL-C, solidifying their role in managing cardiovascular disease.

Beyond their established lipid-lowering effects, the continued refinement of pharmacological strategies has expanded therapeutic horizons, leading to the development of multifaceted treatment modalities that extend beyond hypercholesterolemia. Contemporary pharmaceutical innovations have reformed dyslipidemia management, integrating targeted therapies and pleiotropic drug effects to enhance patient outcomes. This evolving landscape has also catalysed the emergence of antihypertensive agents, reinforcing the interconnected nature of lipid and blood pressure regulation within the broader framework of cardiovascular risk mitigation.

Looking ahead, the future of pharmacotherapy is poised for further innovation, leveraging advancements in precision medicine, genomics, and biotechnological applications to optimize therapeutic efficacy. The integration of biomarker-driven drug development and individualized treatment protocols will play a pivotal role in refining clinical decision-making, ensuring tailored approaches that address patient-specific pathophysiological profiles. As research continues to uncover novel mechanistic insights and therapeutic targets, the dynamic interplay between lipid disorders, hypertension, and systemic vascular health will shape the next generation of pharmaceutical interventions.

REFERENCES:

[1] Bellosta, S., Paoletti, R., & Corsini, A. (1998). History and development of HMG-CoA reductase inhibitors. Milestones in Drug Therapy, 1–17. https://doi.org/10.1007/978-3-0348-8135-7_1

[2] Bhardwaj, S., & Bhattacharyya, K. (2023). Pleiotropic effects of statins: Beyond lipid-lowering properties. Toxicology Letters, 378(2), 107-120. https://doi.org/10.1016/j.toxlet.2023.04.015

[3] Wan, J., & Chen, M. (2023). Effects of statins on hypertension patients: A systematic review and meta-analysis. European Journal of Inflammation, 21(1), 1–6. https://doi.org/10.1177/1721727X221144454

[4] Koh, K. K. (2000). Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovascular Research, 47(4), 648–657. https://doi.org/10.1016/S0008-6363(00)00146-2

[5] Wallace, A., Albadawi, H., Hoang, P., Fleck, A., Naidu, S., Knuttinen, G., & Oklu, R. (2017). Statins as a preventative therapy for venous thromboembolism. Cardiovascular Diagnosis and Therapy, 7(Suppl 3), S213-S220. https://doi.org/10.21037/cdt.2017.09.12

[6] Jezovnik, M. K., & Poredos, P. (2010). Statins and venous thromboembolism. E-Journal of Cardiology Practice, 9(6).

[7] Mayo Clinic. (2025). Statin side effects: Weigh the benefits and risks. Mayo Clinic.

[8] Rosenson, R. S., & Baker, S. K. (2025). Statin muscle-related adverse events. UpToDate.

[9] Tobert, J. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2(7), 517–526. https://doi.org/10.1038/nrd1112

[10] Seenivasan, A., Subhagar, S., Aravindan, R., & Viruthagiri, T. (2008). Microbial production and biomedical applications of lovastatin. Indian Journal of Pharmaceutical Sciences, 70(6), 701-709. https://doi.org/10.4103/0250-474X.49087

[11] Drugs.com. (2024). List of statins: Uses, types & side effects. Drugs.com.

[12] Endo, A. (2017). Discovery and development of statins. Natural Product Communications, 12(8), 1153–1156. https://doi.org/10.1177/1934578X1701200801

[13] Endo, A. (1988). Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Journal of Molecular Medicine, 66(5), 421–427. https://doi.org/10.1007/BF01745510

[14] Nagaoka, S., & Hara, Y. (2019). Compactin: The discovery of statins, the "penicillin" for cholesterol. Drug Discovery in Japan, 15–34. https://doi.org/10.1007/978-981-13-8906-1

[15] Alberts, A. W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., ... & Thompson, J. (1980). Mevinolin: A highly potent competitive inhibitor of HMG-CoA reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences, 77(7), 3957–3961. https://doi.org/10.1073/pnas.77.7.3957

[16] Tobert, J. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2(7), 517–526. https://doi.org/10.1038/nrd1112

[17] Meštrović, T. (n.d.). Statin history. News-Medical.net.

[18] U.S. Food and Drug Administration. (2007). Statins: A success story involving FDA, academia, and industry. FDA History Corner.

[19] Hajar, R. (2011). Statins: Past and present. Heart Views, 12(3), 121–125. https://doi.org/10.4103/1995-705X.95070

[20] U.S. Food and Drug Administration. (2012). FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Effective Medicine.

[21] European Society of Cardiology. (2024). Lipidology update: Targets and timing of well-established therapies. ESC Council for Cardiology Practice.

[22] Xu, R.-X., & Wu, Y.-J. (2020). Lipid-modifying drugs: Pharmacology and perspectives. Coronary Artery Disease: Therapeutics and Drug Discovery, 133–148. https://doi.org/10.1007/978-981-15-2517-9_5

[23] Rosenson, R. S. (2024). Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease. UpToDate.

[24] U.S. Food and Drug Administration. (2009). Lipitor (Atorvastatin Calcium) prescribing information. FDA Center for Drug Evaluation and Research.

[25] Schachter, M. (2004). Chemical, pharmacokinetic, and pharmacodynamic properties of statins: An update. Fundamental & Clinical Pharmacology, 18(1), 1–10. https://doi:10.1111/j.1472-8206.2004.00299.x

[26] Medscape. (n.d.). Altoprev (lovastatin) dosing, indications, interactions, adverse effects. Medscape Reference.

[27] DrugBank. (n.d.). Lovastatin: Uses, interactions, mechanism of action. DrugBank Online.

[28] Patsnap. (2024). What is the mechanism of Lovastatin? Patsnap Synapse.

[29] U.S. Food and Drug Administration. (2004). Altoprev™ (lovastatin) extended-release tablets: Clinical pharmacology. FDA Drug Label Database.

[30] Cid-Conde, L., & López-Castro, J. (2020). Pharmacokinetic aspects of statins. Cardiovascular Risk Factors in Pathology.

[31] Wikipedia. (n.d.). Lovastatin. Wikipedia, The Free Encyclopedia.

[32] Ying, J., Du, L.-D., & Du, G.-H. (2018). Lovastatin. In Natural Small Molecule Drugs from Plants (pp. 93–99). SpringerLink.

[33] Dietrich, D., & Vederas, J. C. (2014). Lovastatin, compactin, and related anticholesterolemic agents. In Biosynthesis and Molecular Genetics of Fungal Secondary Metabolites (pp. 263–287). Springer.

[34] Statin Answers. (n.d.). Lovastatin - The first statin medications. Statin Answers.

[35] Patel, J. J. (2025). The role of lovastatin in cholesterol management and cardiovascular health: A comprehensive review. International Journal of Scientific & Development Research, 25(2), 152.

[36] American College of Cardiology. (2018). 2018 guideline on the management of blood cholesterol. Journal of the American College of Cardiology.

[37] Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., Saseen, J. J., Smith, S. C. Jr., Sperling, L., Virani, S. S., & Yeboah,J.(2019).2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(e1046–e1081). https://doi.org/10.1161/CIR.0000000000000624

[38] Bpacnz. (2021). Prescribing statins to reduce cardiovascular risk. bpacnz Clinical Guidelines.

[39] Zodda, D., Giammona, R., & Schifilliti, S. (2018). Lipid-lowering therapy: State of the art. Cardiology Research and Practice, 2018, 1–12. https://doi.org/10.1155/2018/7123706

[40] Poli, A. (2007). Atorvastatin: Pharmacological characteristics and lipid-lowering effects. Drugs, 67(1), 3–15. https://doi.org/10.2165/00003495-200767001-00002

[41] Padilla-Padilla, F. G., Ruiz-Bernes, L. N., Román-Pintos, L. M., Peraza-Zaldívar, J. A., Sander-Padilla, J. G., Lugo-Sánchez, L. A., Rios-Brito, K. F., Arguedas-Núñez, M. M., Flores-Huanosta, D., & González-Canudas, J. (2025). Efficacy and safety of the fixed-dose combination of atorvastatin/fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia. Cardiology and Therapy, 14, 297–314. https://doi.org/10.1007/s40119-025-00410-y

[42] Nagesh, C., Prashanth Kumar, H. N., Harish, M., Sandip, M., Jeet Bahadur, M., Ankit, A., & Vinay, C. H. (2019). Bioavailability improvement approaches of atorvastatin: A review. International Journal of Pharmacy and Pharmaceutical Research, 16(2), 39–50. Retrieved from Human Journals

[43] Lennernäs, H. (2003). Clinical pharmacokinetics of atorvastatin. Clinical Pharmacokinetics, 42(13), 1141–1160. https://doi.org/10.2165/00003088-200342130-00005

[44] Malhotra, H. S., & Goa, K. L. (2001). Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia. Drugs, 61(12), 1835–1881. https://doi.org/10.2165/00003495-200161120-00012

[45] Lins, R. L., Matthys, K. E., Verpooten, G. A., Peeters, P. C., Dratwa, M., Stolear, J.-C., & Lameire, N. H. (2003). Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrology Dialysis Transplantation, 18(5), 967–976. https://doi.org/10.1093/ndt/gfg048

[46] Sever, P. S., Rostamian, S., Whiteley, W., Ariti, C., Godec, T., Gupta, A., Mackay, J., Whitehouse, A., & Poulter, N. R. (2025). Long-term benefits of atorvastatin on the incidence of cardiovascular events: The ASCOT-Legacy 20-year follow-up. Heart.

[47] Sadowska, A., Osiński, P., Roztocka, A., Kaczmarz-Chojnacka, K., Zapora, E., Sawicka, D., & Car, H. (2024). Statins—From fungi to pharmacy. International Journal of Molecular Sciences, 25(1), 466. https://doi.org/10.3390/ijms25010466

[48] Wikipedia. (n.d.). Atorvastatin. Wikipedia, The Free Encyclopedia.

[49] American Heart Association. (2018). 2018 guideline on the management of blood cholesterol. Circulation, 139(e1046–e1081).

[50] Vorla, M., Daga, P., Umer, M., Shotwell, M. K., & Kalra, D. K. (2023). Beneficial effect of statins in chronic kidney disease: A meta-analysis. National Lipid Association Scientific Sessions 2023.

[51] Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2024). Statin therapy in primary and secondary cardiovascular disease prevention. Current Atherosclerosis Reports, 27, 21. https://doi.org/10.1007/s11883-024-01265-9

[52] Drugs.com. (2024). Fluvastatin sodium monograph. Drugs.com.

[53] American College of Cardiology. (2020). Familial hypercholesterolemia: Cardiovascular risk stratification and clinical management. Journal of the American College of Cardiology.

[54] American Heart Association. (2025). Recommendations for management of clinically significant drug-drug interactions with statins. Circulation, 152(6), e456–e478.

[55] Medicine India. (n.d.). Fluvastatin pharmacology & usage details. Medicine India.

[56] Scripture, C. D., & Pieper, J. A. (2001). Clinical pharmacokinetics of fluvastatin. Clinical Pharmacokinetics, 40(4), 263–281. https://doi.org/10.2165/00003088-200140040-00003

[57] Medsafe. (2014). Statins and CYP interactions. Prescriber Update, 35(1), 12–13.

[58] Toda, T., Eliasson, E., Ask, B., Inotsume, N., & Rane, A. (2009). Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic & Clinical Pharmacology & Toxicology, 105(4), 327–332. https://doi.org/10.1111/j.1742-7843.2009.00453.x

[59] Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000). Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. European Journal of Clinical Pharmacology, 56(3), 225–229. https://doi.org/10.1007/s002280000127

[60] Medicine.com. (2020). Fluvastatin: Dosage, mechanism/onset of action, half-life. Medicine.com.

[61] Wikipedia. (n.d.). Fluvastatin. Wikipedia, The Free Encyclopedia.

[62] Insull, W. Jr., Marais, A. D., Aronson, R., Manfreda, S., & the Fluvastatin Study Group. (2004). Efficacy and safety of fluvastatin ER 80 mg compared with fluvastatin IR 40 mg in the treatment of primary hypercholesterolaemia. The British Journal of Cardiology.

[63] MedCentral. (2025). Fluvastatin: Uses, dosing, warnings, adverse events, interactions. MedCentral Drug Monograph.

[64] Food and Drug Administration. (2001). Pravachol (pravastatin sodium) tablets: Clinical pharmacology and prescribing information. FDA Drug Labeling Database.

[65] Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, J., Glasziou, P., White, H., Barter, P., & Tonkin, A. (2004). Effects of pravastatin on coronary events in patients with low levels of both LDL-C and HDL-C: Results from the LIPID study. European Heart Journal, 25(9), 771–777. https://doi.org/10.1016/j.ehj.2004.03.013

[66] Kang, S. Y., Jeon, T. H., Yum, K.-S., Sunwoo, S., Shin, H.-Y., Kim, D. H., Kim, K., Yoon, J. L., Choi, J.-K., & Kim, Y. S. (2021). Relationship between dietary habits and control of lipid profiles in patients with dyslipidemia using pravastatin. Nutrients, 13(11), 3784. https://doi.org/10.3390/nu13113784

[67] Keidar, S., Aviram, M., Maor, I., Oiknine, J., & Brook, J. G. (1994). Pravastatin inhibits cellular cholesterol synthesis and increases low-density lipoprotein receptor activity in macrophages: In vitro and in vivo studies. British Journal of Clinical Pharmacology, 38(6), 513–519. https://doi.org/10.1111/j.1365-2125.1994.tb04392.x

[68] Hatanaka,T.(2000).Clinical pharmacokinetics of pravastatin. Clinical Pharmacokinetics,39(6),397–412.https://doi.org/10.2165/00003088-200039060-00002

[69] Althanoon, Z., Faisal, I. M., Ahmad, A. A., & Merkhan, M. M. (2020). Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Systematic Reviews in Pharmacy, 11(7), 167–171.

[70] Hosobuchi, M., Shioiri, T., Ohyama, J., Arai, M., Iwado, S., & Yoshikawa, H. (1993). Production of ML-236B, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, by Penicillium citrinum: Improvements of strain and culture conditions. Bioscience, Biotechnology, and Biochemistry, 57(9), 1414–1419. https://doi.org/10.1271/bbb.57.1414

[71] Hara, Y., & Nagaoka, S. (2019). Pravastatin (Pravachol, Mevalotin): "Blockbuster" statin discovered from the metabolites of compactin. Drug Discovery in Japan, 35–49. https://doi.org/10.1007/978-981-13-8906-1_3

[72] American College of Cardiology. (2022). Comparing guideline recommendations of statin use for the primary prevention of ASCVD. ACC Expert Analysis.

[73] Sommeijer, D. W., MacGillavry, M. R., Meijers, J. C. M., Van Zanten, A. P., Reitsma, P. H., & Ten Cate, H. (2004). Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care, 27(2), 468–473. https://doi.org/10.2337/diacare.27.2.468

[74] Food and Drug Administration. (2005). Crestor (rosuvastatin calcium) tablets: Clinical pharmacology and prescribing information. FDA Drug Labeling Database.

[75] Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012). Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology, 6, 17–33. https://doi.org/10.4137/CMC.S4324

[76] European Society of Cardiology. (2019). 2019 guidelines on dyslipidaemias (management of). European Heart Journal.

[77] European Society of Cardiology. (2021). Lipid-lowering treatment in secondary prevention. European Heart Journal.

[78] Kostapanos, M. S., Milionis, H. J., Filippatos, T. D., Christogiannis, L. G., Bairaktari, E. T., Tselepis, A. D., & Elisaf, M. S. (2009). Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 14(1), 5–13. https://doi.org/10.1177/1074248408331031

[79] Bielecka-Dabrowa, A., Bytyçi, I., Von Haehling, S., Anker, S., Jozwiak, J., Rysz, J., Hernandez, A. V., Bajraktari, G., Mikhalidis, D. P., & Banach, M. (2019). Association of statin use and clinical outcomes in heart failure patients: A systematic review and meta-analysis. Lipids in Health and Disease, 18, 188. https://doi.org/10.1186/s12944-019-

1135-z
[80] AstraZeneca. (2025). Pharmacokinetics and drug interactions of Crestor (rosuvastatin). Crestor Prescribing Information.
[81] Biocon. (2025). Rosuvastatin tablets prescribing information. Biocon Pharmaceuticals.
[82] Calza, L. (2004). Long-term use of rosuvastatin: A critical risk-benefit appraisal and comparison with other antihyperlipidemics. Drug, Healthcare and Patient Safety.
[83] Food and Drug Administration. (2003). Crestor (rosuvastatin calcium) tablets: Clinical pharmacology and prescribing information. FDA Drug Labeling Database.
[84] Ashraf, I., Hanna, P. A., Gad, S., Abd-Allah, F. I., & El-Say, K. M. (2023). Enhancing pharmacokinetics and pharmacodynamics of rosuvastatin calcium through the development and optimization of fast-dissolving films. Pharmaceutics, 15(11), 2640. https://doi.org/10.3390/pharmaceutics15112640
[85] Chatzizisis, Y. S., Koskinas, K. C., Misirli, G., Vaklavas, C., Hatzitolios, A., & Giannoglou, G. D. (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention, and treatment. Drug Safety, 33(3), 171–187. https://doi.org/10.2165/11319380-000000000-00000
[86] Zhou, S., Chen, R., Liu, J., et al. (2024). Comparative effectiveness and safety of atorvastatin versus rosuvastatin: A multi-database cohort study. Annals of Internal Medicine.
[87] Food and Drug Administration. (2010). Zocor (simvastatin) tablets: Prescribing information. FDA Drug Labeling Database.
[88] UpToDate. (2025). Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. UpToDate.
[89] Pyörälä, K., Ballantyne, C. M., Gumbiner, B., Lee, M. W., Shah, A., Davies, M. J., Mitchel, Y. B., Pedersen, T. R., & Kjekshus, J. (2004). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 27(7), 1735–1740. https://doi.org/10.2337/diacare.27.7.1735
[90] Yin, W., Alwabli, R. I., Attwa, M. W., Rahman, A. F. M. M., & Kadi, A. A. (2022). Simvastatin: In vitro metabolic profiling of a potent competitive HMG-CoA reductase inhibitor. Separations, 9(12), 400. https://doi.org/10.3390/separations9120400
[91] Lakoski, S. G., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., & Cohen, J. C. (2010). Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. The Journal of Clinical Endocrinology & Metabolism, 95(2), 800–809. https://doi.org/10.1210/jc.2009-1952
[92] Bruckert, E. (2005). Impact of lipid treatment on cardiovascular risk reduction: New therapeutic targets. European Heart Journal Supplements, 7(suppl_L), L16–L20. https://doi.org/10.1093/eurheartj/sui081
[93] DeCristofaro, C. (2025). Substrates, inhibitors, and inducers of CYP3A4. Medical University of South Carolina.
[94] Mauro, V. F. (1993). Clinical pharmacokinetics and practical applications of simvastatin. Clinical Pharmacokinetics, 24(3), 195–202. https://doi.org/10.2165/00003088-199324030-00002
[95] Medicine.com. (2020). Simvastatin: Dosage, mechanism/onset of action, half-life. Medicine.com.
[96] Barrios-González, J., Pérez-Sánchez, A., & Bibián, M. E. (2020). New knowledge about the biosynthesis of lovastatin and its production by fermentation of Aspergillus terreus. Applied Microbiology and Biotechnology, 104(9), 8979–8998. https://doi.org/ 10.1007/s00253-020-10871-x
[97] Food and Drug Administration. (2007). Drug approval package: Zocor (Simvastatin) NDA# 19-766/S27. FDA Drug Labeling Database.
[98] Talreja, O., Kerndt, C. C., & Cassagnol, M. (2023). Simvastatin: A semi-synthetic derivative of lovastatin with optimized LDL-C reduction and safety profile. Europe PMC.
[99] Hot, A., Lavocat, F., Lenief, V., & Miossec, P. (2013). Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Annals of the Rheumatic Diseases, 72(5), 754–761. https://doi.org/10.1136/annrheumdis-2012-201887